Update on romiplostim and eltrombopag indirect comparison.
نویسندگان
چکیده
1. Husereau D, DrummondM, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Int J Technol Assess in Health Care. 2013;29:117-122. 2. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost-effectiveness studies: Systematic review. BMJ. 2006;332:699-703. 3. Peura PK, Martikainen JA, Purmonen TT, Turunen JH. Sponsorshiprelated outcome selection bias in published economic studies of triptans: Systematic review. Med Decis Making. 2012;32:237-245. 4. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ. 2003;326:1167-1170. 5. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: Funding sources and outcomes. Int J Technol Assess in Health Care. 2010;26:330-333. 6. Drummond MF. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? Pharmacoeconomics. 1988;14:1-9. 7. Morgan S, Barer M, Evans R. Health economists meet the fourth tempter: Drug dependency and scientific discourse. Health Econ. 2000;9:659 -667. 8. Barbieri M, Drummond MF. Conflict of interest in industry-sponsored economic evaluations: Real or imagined? Curr Oncol Rep. 2001;3:410413.
منابع مشابه
Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
OBJECTIVES Immune thrombocytopenia (ITP) causes increased platelet destruction and suboptimal platelet production, increasing risk of bleeding. This analysis uses a Bayesian metaregression model to indirectly compare effectiveness of the thrombopoietin mimetics romiplostim and eltrombopag for increasing platelet counts, and contrasts the results with those of non-Bayesian approaches. METHODS ...
متن کاملA Comment on Boyers et al.: “Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal”
In their publication of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal of eltrombopag, Boyers et al. [1] report the results of the indirect treatment comparison (ITC) of eltrombopag and romiplostim, conducted by GlaxoSmithKline (GSK) [the manufacturer of eltrombopag] and made available to NICE as part of the single technology appraisal of eltrombopa...
متن کاملThrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand.
BACKGROUND Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the treatment of immune thrombocytopenia (ITP). Based on our experience, the incidence of abortive treatment with these drugs and the occurrence of adverse reactions that lead to therapy break-off despite response are higher than has been previously suggested. METHODS During...
متن کاملErratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
BACKGROUND Romiplostim, a thrombopoietin receptor agonist (TPOra), is a second-line medical treatment option for adults with chronic immune thrombocytopenia (ITP). Clinical trials have shown that romiplostim increases platelet counts, while reducing the risk of bleeding and, in turn, the need for costly rescue medications. AIMS The objective of this study was to assess the cost effectiveness ...
متن کاملA retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
Romiplostim and eltrombopag, the first thrombopoietic receptor-agonists with demonstrated efficacy against immune thrombocytopenia in prospective controlled studies, were recently authorized in most countries for adults with chronic immune thrombocytopenia. So far, no data are available about the potential contribution of switching from romiplostim to eltrombopag or vice versa in terms of effic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- International journal of technology assessment in health care
دوره 30 1 شماره
صفحات -
تاریخ انتشار 2014